Premium
Topical tacrolimus is effective against eczema in Wiskott‐Aldrich syndrome (WAS)
Author(s) -
Bienemann Klaus,
Gudowius Sonja,
Niehues Tim
Publication year - 2007
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2007.00044.x
Subject(s) - wiskott–aldrich syndrome , medicine , tacrolimus , dermatology , immunodeficiency , calcineurin , immunology , immunopathology , wiskott–aldrich syndrome protein , surgery , transplantation , immune system , genetics , actin cytoskeleton , cytoskeleton , gene , cell , biology
The Wiskott‐Aldrich syndrome is a rare X‐linked immunodeficiency characterized by microplatelet thrombocytopenia and eczema. Eczema may be severe and facilitate entry of microorganism into the host. Conclusion: We report for the first time that eczema in infants with WAS can be effectively treated with topical tacrolimus.